Literature DB >> 20492463

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels.

N Hickson1, D Hampshire, P Winship, J Goudemand, R Schneppenheim, U Budde, G Castaman, F Rodeghiero, A B Federici, P James, I Peake, J Eikenboom, A Goodeve.   

Abstract

BACKGROUND: von Willebrand factor (VWF) variant c.2771G>A; p.R924Q has been described as a benign polymorphism or a possible marker for a null allele and been associated with mild bleeding phenotypes. It was identified in several patients in recent type 1 von Willebrand disease (VWD) studies.
OBJECTIVES: To determine whether the p.R924Q allele contributes to reduced VWF levels and type 1 VWD.
METHODS: One thousand one hundred and fifteen healthy controls and 148 index cases from the MCMDM-1VWD study were genotyped for c.2771G>A; VWF and FVIII levels were analyzed in ABO blood group stratified individuals and the p.R924Q variant was expressed in 293 EBNA cells.
RESULTS: c.2771G>A was present in six index cases, five of whom had a second VWF variant which probably contributed to the phenotype. A common core haplotype identified in families, which included the rare G allele of c.5843-8C>G, was present in the majority of 35 c.2771G>A heterozygous controls. c.2771G>A contributed about 10% variance in VWF and FVIII levels in controls and 35% variance when co-inherited with blood group O. Recombinant p.R924Q VWF had no effect on in vitro expression and heterozygous family members had normal VWF-FVIII binding and normal clearance of VWF and FVIII.
CONCLUSIONS: The allele bearing c.2771A leads to reductions in VWF and FVIII levels particularly in combination with blood group O. Its inheritance alone may be insufficient for VWD diagnosis, but it appears to be associated with a further VWF level reduction in individuals with a second VWF mutation and it contributes to population variance in VWF and FVIII levels.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492463      PMCID: PMC3856360          DOI: 10.1111/j.1538-7836.2010.03927.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  20 in total

1.  Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD.

Authors:  J Eikenboom; V Van Marion; H Putter; A Goodeve; F Rodeghiero; G Castaman; A B Federici; J Batlle; D Meyer; C Mazurier; J Goudemand; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

2.  A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).

Authors:  A Tosetto; F Rodeghiero; G Castaman; A Goodeve; A B Federici; J Batlle; D Meyer; E Fressinaud; C Mazurier; J Goudemand; J Eikenboom; R Schneppenheim; U Budde; J Ingerslev; Z Vorlova; D Habart; L Holmberg; S Lethagen; J Pasi; F Hill; I Peake
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

3.  R924Q substitution encoded within exon 21 of the von Willebrand factor gene related to mild bleeding phenotype.

Authors:  Patricia Casais; Gonzalo A Carballo; Adriana I Woods; Ana C Kempfer; Cristina E Farías; Silvia H Grosso; María A Lazzari
Journal:  Thromb Haemost       Date:  2006-08       Impact factor: 5.249

4.  An assessment of the pathogenic significance of the R924Q von Willebrand factor substitution.

Authors:  E Berber; P D James; C Hough; D Lillicrap
Journal:  J Thromb Haemost       Date:  2009-07-17       Impact factor: 5.824

5.  Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project.

Authors:  Juan Carlos Souto; Laura Almasy; Jose Manuel Soria; Alfonso Buil; William Stone; Mark Lathrop; John Blangero; Jordi Fontcuberta
Journal:  Thromb Haemost       Date:  2003-03       Impact factor: 5.249

Review 6.  Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology.

Authors:  J C Eikenboom
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

7.  Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents.

Authors:  Claudine Caron; Claudine Mazurier; Jenny Goudemand
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

8.  An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease.

Authors:  Anthony Cumming; Pamela Grundy; Stephen Keeney; William Lester; Said Enayat; Andrea Guilliatt; Derrick Bowen; John Pasi; David Keeling; Frank Hill; Paula H B Bolton-Maggs; Charles Hay; Peter Collins
Journal:  Thromb Haemost       Date:  2006-11       Impact factor: 5.249

9.  Relationship among Lewis phenotype, clotting factors, and other cardiovascular risk factors in young adults.

Authors:  D Green; O Jarrett; K J Ruth; A R Folsom; K Liu
Journal:  J Lab Clin Med       Date:  1995-03

10.  Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor.

Authors:  K H Orstavik; L Kornstad; H Reisner; K Berg
Journal:  Blood       Date:  1989-03       Impact factor: 22.113

View more
  7 in total

Review 1.  von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies.

Authors:  Paula D James; David Lillicrap
Journal:  Am J Hematol       Date:  2012-03-03       Impact factor: 10.047

2.  Functional characterisation of the type 1 von Willebrand disease candidate VWF gene variants: p.M771I, p.L881R and p.P1413L.

Authors:  Ergul Berber; Mehmet Ozbil; Christine Brown; Zafer Baslar; S Hande Caglayan; David Lillicrap
Journal:  Blood Transfus       Date:  2016-07-25       Impact factor: 3.443

3.  Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease.

Authors:  Junmei Chen; Jesse D Hinckley; Sandra Haberichter; Paula Jacobi; Robert Montgomery; Veronica H Flood; Randall Wong; Gianluca Interlandi; Dominic W Chung; José A López; Jorge Di Paola
Journal:  Blood       Date:  2015-05-27       Impact factor: 22.113

Review 4.  von Willebrand disease.

Authors:  Paula D James; Anne C Goodeve
Journal:  Genet Med       Date:  2011-05       Impact factor: 8.822

5.  Noncanonical type 2B von Willebrand disease associated with mutations in the VWF D'D3 and D4 domains.

Authors:  Monica Sacco; Stefano Lancellotti; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti; Maira Tardugno; Erica De Candia; Leonardo Di Gennaro; Maria Basso; Betti Giusti; Massimiliano Papi; Giordano Perini; Giancarlo Castaman; Raimondo De Cristofaro
Journal:  Blood Adv       Date:  2020-07-28

6.  Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS.

Authors:  Luciano Baronciani; Ian Peake; Reinhard Schneppenheim; Anne Goodeve; Minoo Ahmadinejad; Zahra Badiee; Mohammad-Reza Baghaipour; Olga Benitez; Imre Bodó; Ulrich Budde; Andrea Cairo; Giancarlo Castaman; Peyman Eshghi; Jenny Goudemand; Wolf Hassenpflug; Hamid Hoorfar; Mehran Karimi; Bijan Keikhaei; Riitta Lassila; Frank W G Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M K Zetterberg; Jeroen Eikenboom; Augusto B Federici; Flora Peyvandi
Journal:  Blood Adv       Date:  2021-08-10

7.  Combined effects of two mutations in von Willebrand disease 2M phenotype.

Authors:  Adriana I Woods; Juvenal Paiva; Ana C Kempfer; Debora M Primrose; Alicia N Blanco; Analía Sanchez-Luceros; María A Lazzari
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.